Avicanna Inc. is a biopharmaceutical company focused on developing evidence-based products for the medical and pharmaceutical sectors. Key concerns include negative EBITDA and net margins, indicating ongoing operational losses, while a gross margin of 56.6% suggests potential for profitability if costs are managed. The current and quick ratios below 1 raise liquidity concerns, although a low debt-to-equity ratio of 0.04 indicates minimal leverage. Overall, while the company has strong product margins, its financial health and liquidity pose significant challenges.
Loading financial metrics...
Company has $200K in cash but burned $746K last quarter. At this burn rate, only 0.3 quarters of runway remain without additional financing.
Company posted a loss of $-3.7M over the last year, representing 14.8% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $3.0M over the last year.
Debt increased 357.1% from $37K to $170K while revenue growth remained modest.
Strong gross margin of 55.4% reflects healthy unit economics.
Strong balance sheet with net cash position provides cushion for growth investments.
Low debt-to-revenue ratio of 0.7% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)